Retatrutide is a triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously, distinguishing it from approved agents such as semaglutide or tirzepatide
Nitric oxide suppresses permeability transition pore opening and enhances calcium uptake in mitochondria in vivo
They do not replace proper medical treatment
Inflammation is one of the main causes of many autoimmune diseases in our body
Extended-release formulation patents tend to face significant inventive step challenges at the EPO, because the prior art literature on controlled-release polymer technology is extensive and examiners are familiar with it
Ipamorelin is a selective growth hormone secretagogue, meaning it targets the pituitary gland to release GH without causing a significant rise in cortisol, a stress hormone that can interfere with muscle recovery